RE:RE:RE:RE:RE:RE:RE:RE:RE:Moving at pacemy 5 cents is, these targeted acquisitions find differing valuation metrics ie RXi is very different to VisionPros as is Oncidium.
Example: youre buying patents with VisionPros and 1MM clients of which 18% are subscription vs RXi who are more of a retail volume type business....and then there is Oncidium today that brings 2MM lives with it.....all of these things add up differently(which is where investment banks advising DOC earn their money).....remember one key metric, it is better to acquire a high quality company that has a large client base as it will always cost you tons of $$$ and time to do this yourself...and retain them....DOC has an immediate ability to cross sell so that has value etc etc.
What was a nice change today was the DOC shares offered in the deal being $2.30ea vs "most recent 10 days trading avg" per previous deals. Also, there is the 30 month earn-out so everyone is aligned to make this a success just like prior deal terms as well.